Zhun Yu^1,2, Jie Wang^1,2, Guoping Xu^1,2,*

Oncology Research, Vol.33, No.8, pp. 2013-2035, 2025, DOI:10.32604/or.2025.061757 - 18 July 2025

Abstract Objectives: Triple-negative breast cancer (TNBC) presents a major treatment challenge due to its aggressive behavior. The dysfunction of the Golgi apparatus (GA) contributes to the development of various cancers. This study aimed to utilize GA-related genes (GARGs) to forecast the prognosis and immune profile of TNBC. Methods: The data were downloaded from The Cancer Genome Atlas (TCGA) database, including 175 TNBC and 99 healthy samples. The differentially expressed GARGs (DEGARGs) were analyzed using the TCGA biolinks package. The patients with TNBC were classified into two clusters utilizing the ConsensusClusterPlus package according to prognosis-related DEGARGs, followed by… More >

YU QIU^1,#, RUIHAN LIU^2,#, SHANSHAN HUANG¹, QIAOTING CAI¹, YI XIE¹, ZHITING HE¹, WEIGE TAN^2,*, XINHUA XIE^1,*

Oncology Research, Vol.33, No.5, pp. 1135-1147, 2025, DOI:10.32604/or.2025.062767 - 18 April 2025

Abstract Objectives: Deubiquitinase OTUB2 plays a critical role in the progression of various tumors. However, its specific role in triple-negative breast cancer (TNBC) remains unclear. This study aims to elucidate the biological function of OTUB2 in TNBC and uncover the underlying mechanisms. Methods: First, we found that the expression of OTUB2 was upregulated in TNBC by bioinformatics analysis, we then validated its expression in TNBC tissues and cells using immunohistochemistry (IHC) and qPCR and plotted the survival curves by Kaplan-Meier method. Gene set enrichment analysis (GSEA) suggested that OTUB2 may be involved in tumor proliferation and metastasis.… More > Graphic Abstract

LI SUN^1,#, SHICHAO ZHUO^2,#, XIAOXIN LI², HUSHENG KONG³, WEIWEI DU³, CHONG ZHOU⁴, JUNXING HUANG^1,*

Oncology Research, Vol.33, No.3, pp. 641-651, 2025, DOI:10.32604/or.2024.050057 - 28 February 2025

Abstract Background: Cisplatin (DDP) has been used in the treatment of various human cancers. However, DDP alone lacks efficacy in treating triple-negative breast cancer (TNBC), and its clinical application is often hampered by side effects. Astragalus polysaccharide (APS) is one of the active components extracted from Astragalus membranaceus and has gained attention for its various biological properties. This research is aimed to evaluate the effectiveness of a combination of APS and DDP on TNBC and explore the potential mechanisms. Methods: The efficacy and mechanisms of single or combined treatment were evaluated using Cell Counting Kit-8 (CCK8) assay, Annexin… More >

XIANG LI^1,#, WENKE JIN^2,#, LIFENG WU², HUAN WANG¹, XIN XIE¹, WEI HUANG^1,*, BO LIU^2,*

Oncology Research, Vol.33, No.1, pp. 67-81, 2025, DOI:10.32604/or.2024.055921 - 20 December 2024

Abstract Background: Triple-negative breast cancer (TNBC), characterized by its lack of traditional hormone receptors and HER2, presents a significant challenge in oncology due to its poor response to conventional therapies. Autophagy is an important process for maintaining cellular homeostasis, and there are currently autophagy biomarkers that play an effective role in the clinical treatment of tumors. In contrast to targeting protein activity, intervention with protein-protein interaction (PPI) can avoid unrelated crosstalk and regulate the autophagy process with minimal interference pathways. Methods: Here, we employed Naive Bayes, Decision Tree, and k-Nearest Neighbors to elucidate the complex PPI… More >

Leonard Lothstein^*, Judith Soberman^†, Deanna Parke^*, Jatin Gandhi^*, Trevor Sweatman^‡, Tiffany Seagroves^*

Oncology Research, Vol.28, No.5, pp. 451-465, 2020, DOI:10.3727/096504020X15898794315356

Abstract Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of drug resistance and cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC. Pivarubicin directly activates PKCd, triggers rapid mitochondrial-dependent apoptosis, and… More >

Guoqiang Zhang^*1, Zengyan Liu^†1, Yong Han^*, Xiaohong Wang^*, Zhenlin Yang^*

Oncology Research, Vol.24, No.4, pp. 233-238, 2016, DOI:10.3727/096504016X14648701447977

Abstract Triple-negative breast cancer (TNBC) is associated with high recurrence rates of metastasis and death. miR-509 has been reported to be a tumor suppressor in many cancers, but its effect in TNBC has not yet been identified. In this article, we explored the effects of miR-509 on the malignant phenotype of TNBC cells, including proliferation, apoptosis, migration, and invasion. We transiently transfected TNBC cells, Hs578T, with miR-509 mimic. Upon transfection, the expression of miR-509 was upregulated about 50-fold compared with cells transfected with scramble mimic. Overexpression of miR-509 inhibited cell proliferation, induced cell apoptosis, and suppressed More >